Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.7K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

377
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
377
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

337
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

482
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

804
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
804
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

750
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
750

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing child health: forecasting the next great research achievements.

Pediatric research·2026
Same author

A Multiomics Approach to Defining Target-Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort.

Journal of the American Heart Association·2025
Same author

Accelerating Guideline-Recommended Universal Pediatric Lipid Screening: Launch of the LEAD Pediatric Initiative.

The Journal of pediatrics·2025
Same author

Ambulatory blood pressure variability in prediction of target organ injury: the SHIP AHOY study.

Pediatric nephrology (Berlin, Germany)·2025
Same author

The association of childhood HDL cholesterol with atherosclerotic cardiovascular disease events in adults: findings from the International Childhood Cardiovascular Cohort Consortium.

European journal of preventive cardiology·2025
Same author

Youth Blood Pressure and Target Organ Injury Markers: The SHIP AHOY Study.

Hypertension (Dallas, Tex. : 1979)·2025

Related Experiment Video

Updated: Apr 4, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K

Pediatric guidelines for dyslipidemia.

Stephen R Daniels1

  • 1Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.

Journal of Clinical Lipidology
|September 8, 2015
PubMed
Summary

Pediatric dyslipidemia guidelines recommend universal screening at ages 9-11 to detect genetic conditions like familial hypercholesterolemia. The guidelines also offer lifestyle and pharmacologic advice for children with high cholesterol.

Keywords:
DyslipidemiaEvidence reviewFamilial hypercholesterolemiaGuidelinesPediatric

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.9K

Related Experiment Videos

Last Updated: Apr 4, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.9K

Area of Science:

  • Cardiology
  • Pediatrics
  • Public Health

Background:

  • Clinical guidelines aid complex decision-making, involving systematic literature reviews and evidence grading.
  • Pediatric dyslipidemia guidelines were first established in 1992, with a significant gap before the next publication.

Purpose of the Study:

  • To review and update clinical guidelines for pediatric dyslipidemia based on current evidence.
  • To provide evidence-based recommendations for screening, lifestyle modification, and pharmacologic treatment of dyslipidemia in children.

Main Methods:

  • A systematic review of relevant literature was conducted.
  • Evidence was graded to inform the development of clinical recommendations.
  • The review process spanned from 2006 to 2008, with publication in 2011.

Main Results:

  • The 2011 guidelines recommend universal dyslipidemia screening for children aged 9 to 11 years.
  • Emphasis is placed on identifying genetic dyslipidemias, such as familial hypercholesterolemia.
  • Recommendations include lifestyle interventions and pharmacologic treatment for severely elevated low-density lipoprotein cholesterol.

Conclusions:

  • The guideline development process requires ongoing review and implementation assessment.
  • Continuous evaluation of new research is crucial for updating clinical guidelines.
  • These guidelines aim to improve cardiovascular disease risk reduction in children.